HC Wainwright Lowers Earnings Estimates for Microbot Medical

Microbot Medical Inc. (NASDAQ:MBOT) – Research analysts at HC Wainwright cut their Q3 2026 EPS estimates for shares of Microbot Medical in a note issued to investors on Wednesday, August 19th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings per share of ($0.08) for the quarter, down from their prior forecast of ($0.06). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Microbot Medical’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.28) EPS.

Several other equities analysts have also weighed in on the stock. Wall Street Zen raised shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Zacks Research raised shares of Microbot Medical from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 22nd. B. Riley Financial restated a “buy” rating and set a $4.00 price target (down from $5.00) on shares of Microbot Medical in a research note on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a report on Wednesday, July 8th. Finally, Loop Capital set a $4.00 price objective on shares of Microbot Medical in a research note on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Microbot Medical presently has an average rating of “Moderate Buy” and a consensus price target of $6.38.

Microbot Medical Stock Performance

Shares of NASDAQ MBOT opened at $1.49 on Friday. The stock has a market cap of $100.08 million, a price-to-earnings ratio of -6.21 and a beta of 1.06. The business has a 50 day simple moving average of $1.79 and a 200 day simple moving average of $2.05. Microbot Medical has a 52 week low of $1.44 and a 52 week high of $4.67.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million.

Institutional Investors Weigh In On Microbot Medical

A number of large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. bought a new position in shares of Microbot Medical in the first quarter valued at approximately $57,000. Geode Capital Management LLC boosted its holdings in shares of Microbot Medical by 24.7% during the 2nd quarter. Geode Capital Management LLC now owns 395,039 shares of the biotechnology company’s stock worth $996,000 after buying an additional 78,121 shares during the period. American Century Companies Inc. bought a new stake in shares of Microbot Medical during the 2nd quarter worth $32,000. XTX Topco Ltd acquired a new position in Microbot Medical in the 2nd quarter valued at $43,000. Finally, Envestnet Asset Management Inc. acquired a new position in Microbot Medical in the 3rd quarter valued at $98,000. Institutional investors own 16.30% of the company’s stock.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.